Skip to content
Open access

Predictors of Virologic Failure Among Adults with Low-Level Viremia: A Retrospective Cohort Study in Oromia, Ethiopia

Oct 2026 · International Journal of Modern Science and Research Technology · 0 citations · 9 references

TL;DR

A retrospective cohort study among adults with at least one LLV episode documented between October 2023 and June 2025 across 105 health facilities in Oromia, Ethiopia and evaluated predictors of progression from LLV to virologic failure and characterized the time-dependent probability of progression in a large Ethiopian ART cohort.

Abstract

Low-level viremia (LLV), defined as an HIV-1 RNA level of 50 to 999 copies/mL, is a common but clinically challenging state among adults receiving antiretroviral therapy (ART). Although LLV does not meet the conventional threshold for virologic failure, it may identify individuals at increased risk of subsequent treatment failure. We evaluated predictors of progression from LLV to virologic failure and characterized the time-dependent probability of progression in a large Ethiopian ART cohort. Methods We conducted a retrospective cohort study among adults with at least one LLV episode documented between October 2023 and June 2025 across 105 health facilities in Oromia, Ethiopia. The primary outcome was progression from LLV to virologic failure, defined as an HIV-1 RNA level of ≥1000 copies/mL, within 18 months. Predictors were evaluated using generalized estimating equations (GEE) with patient-level clustering. A risk stratification model was derived using L1-penalized logistic regression with a patient-level train/test split and validated using grouped cross-validation. Time to virologic failure was evaluated using Kaplan-Meier methods, with a sensitivity analysis based on alternative censoring definitions. Results Among 6713 LLV observations contributed by 6167 unique patients, 189 virologic failure events occurred over 18 months of follow-up. The cumulative incidence of virologic failure was 0.76% at 6 months, 2.22% at 12 months, and 3.02% at 18 months at the patient level. In multivariable GEE analysis, receipt of second- or third-line ART was strongly associated with increased odds of virologic failure (adjusted odds ratio [aOR], 3.93; 95% CI, 2.85-5.43; P < .001), whereas multi-month dispensing (MMD) of ≥90 days was associated with lower odds of virologic failure (aOR, 0.54; 95% CI, 0.38-0.79; P = .001). Increasing age was independently associated with a modest reduction in the odds of virologic failure (aOR per year, 0.99; 95% CI, 0.98-1.00; P = .046). Sex, adherence status, prior visit frequency, prior viral load documentation, and prior viral load magnitude were not independently associated with virologic failure after adjustment. The risk-stratification model demonstrated moderate discrimination (area under the receiver operating characteristic curve [AUC-ROC], 0.79; precision-recall area under the curve [PR-AUC], 0.09) but poor calibration, with a mean predicted probability of 38.9% compared with an observed event prevalence of 2.23%. Kaplan-Meier analysis estimated a cumulative probability of virologic failure of 1.27% at 6 months, 8.10% at 12 months, and 34.51% (95% CI, 26.31%-44.40%) at 18 months in the primary cohort; estimates were similar in the sensitivity cohort (35.14%; 95% CI, 26.95%-44.95%).

Read PDF

Similar papers

Open access Oct 2026

Risk factors for low-level viremia and virological failure in HIV patients in southwestern China who transitioned to second-line antiretroviral therapy after failure of first-line treatment: a retrospective cohort study

Enhanced monitoring of resistance markers and immunological indicators is warranted among patients receiving second-line ART to facilitate timely clinical evaluation and treatment adjustment in resource-limited settings.

Zong-Yu Nie, Yan Zheng, Liu-Ying Yang et al. · 0 citations
Open access Nov 2026

HIV/AIDS patients with low-level viremia in different states have variable risks of subsequent viral suppression failure: a large retrospective study in Chongqing

To analyze the basic characteristics and influencing factors of low-level viremia (LLV) among treated HIV/AIDS patients in Chongqing and to examine the association between low-level viremia and virological failure. Data from AIDS patients who were diagnosed and treated at the Chongqing Public Health Medical...

Yong-Jian Fu, Kun He, Qian Liu et al. · 0 citations
Open access Oct 2026

Low Prevalence of HIV-1 Antiretroviral Resistance Among Patients Experiencing Virological Failure on Dolutegravir-Based Regimens: A Prospective Cohort Study in Bunia, Democratic Republic of the Congo

The adoption and widespread use of dolutegravir (DTG)-based antiretroviral therapy (ART) are key strategies for achieving global 2030 targets, though emerging resistance threatens long-term success. This study evaluated HIV-1 drug resistance mutations among participants experiencing virological failure in Bunia, Democr...

Alex Liripa Kwendra, A. Mouinga-Ondémé, J. Engone-Ondo et al. · 0 citations
Open access Sep 2026

Genotype-guided antiretroviral therapy outcomes in routine clinical practice: a retrospective study of HIV viral load suppression at 6 and 12 months in Uganda.

This study assessed virological outcomes following genotype-guided antiretroviral therapy (GART). We conducted a retrospective cohort of 235 PLHIV (2021-2023) post-GART after virological failure, analyzing baseline characteristics, 6- and 12-month viral load outcomes, and suppression factors using descriptive statistic...

Collins Ankunda, Jude Emunyu, S. Namasambi et al. · 0 citations
Open access Jan 2026

Nonoptimal Virological Response Among Adults Living With HIV After Initiation of Combined Antiretroviral Therapy at a Tertiary Hospital in Oman: A Retrospective Cohort Study, 1992–2024

Background Combined antiretroviral therapy (cART) has transformed HIV infection from a life‐threatening condition into a manageable chronic disease by reducing viral replication, preserving immune function, and lowering HIV‐related morbidity and mortality. Nevertheless, achieving and maintaining viral suppression remai...

Zainab M. Al-Zadjali, Faryal Khamis, Sanjay Jaju et al. · 0 citations
Review Open access Oct 2026

Virological failure and treatment interruption among people with unsuppressed viral load on antiretroviral therapy: a cross-sectional analysis of Population-based HIV Impact Assessment surveys in seven sub-Saharan African countries.

BACKGROUND Viral load suppression among people with HIV on antiretroviral therapy (ART) remains a priority in sub-Saharan Africa. We aimed to quantify virological failure versus interruption in treatment among people aged 15 years or older with unsuppressed viral load. METHODS In this cross-sectional analysis of nati...

M. Farahani, Suzue Saito, Shannon M. Farley et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.